CNTA insider files Form 144 for 35,000-share sale totaling $840,000

Rhea-AI Filing Summary

Form 144 filed for Centessa Pharmaceuticals plc (CNTA) shows a proposed sale of 35,000 common shares through UBS Financial Services on NASDAQ, with an aggregate market value of $840,000 and an approximate sale date of 09/24/2025. The shares were acquired and paid for on 09/24/2025 by exercise of stock options from the issuer. The filer reported prior open-market sales in the past three months: 24,792 shares on 09/09/2025 for $495,840 and 25,000 shares on 09/10/2025 for $550,000, totaling 49,792 shares and $1,045,840 in gross proceeds. Outstanding shares are listed as 134,073,436, making the proposed 35,000-share sale about 0.026% of outstanding common stock. The filing includes the standard Rule 144 representation regarding material nonpublic information.

Positive

• Transparent disclosure of planned sale details including broker, sale date, share count, and market value
• Seller attestation that no material nonpublic information is known, consistent with Rule 144 requirements
• Prior sales disclosed showing historical trading activity and aggregate proceeds

Negative

• No information on the identity (beyond address in past-sales lines) or role of the seller within the company in this filing
• Insufficient context to assess whether recent sales are part of a systematic liquidity plan (no 10b5-1 plan date provided)

Insights

Securities Analyst

TL;DR: Insider exercised options and is selling a modest position; transaction size is immaterial relative to share count.

The filing documents an option exercise and subsequent planned sale of 35,000 common shares valued at $840,000, executed through UBS, with prior recent dispositions totaling 49,792 shares and $1,045,840 gross proceeds. Compared with the reported 134,073,436 shares outstanding, the proposed sale represents approximately 0.026% of outstanding stock, indicating limited dilution or market impact. The notice follows Rule 144 disclosure mechanics and includes the seller's attestation on material nonpublic information.

Corporate Governance Expert

TL;DR: Filing reflects routine insider liquidity under Rule 144 and standard compliance statements.

The document indicates exercise of stock options and planned open-market sales reported via Form 144. The filing lists the broker, sale dates, and amounts and reiterates the seller's representation about no undisclosed material information. There are no disclosures here of related-party transactions, changes in control, or governance actions. Procedurally, the filing appears to meet Rule 144 reporting requirements for planned dispositions.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	UBS Financial Services Inc. 11 Madison Ave. 4th Floor New York NY 10010	35000	840000.00	134073436	09/24/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	09/24/2025	Exercise of Stock Option	Issuer			35000	09/24/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Tia Bush 3RD FLOOR 1 ASHLEY ROAD ALTRINCHAM, CHESHIRE X0 WA14 2DT	Common	09/09/2025	24792	495840.00
Tia Bush 3RD FLOOR 1 ASHLEY ROAD ALTRINCHAM, CHESHIRE X0 WA14 2DT	Common	09/10/2025	25000	550000.00

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does Centessa (CNTA) Form 144 report on 09/24/2025?

The Form 144 reports a proposed sale of 35,000 common shares through UBS with an aggregate market value of $840,000 and an approximate sale date of 09/24/2025.

How were the 35,000 Centessa shares acquired according to the filing?

The filing states the shares were acquired on 09/24/2025 by exercise of stock options from the issuer and paid for in cash on the same date.

What recent sales by the seller are disclosed in the Form 144?

The seller reported selling 24,792 shares on 09/09/2025 for $495,840 and 25,000 shares on 09/10/2025 for $550,000, totaling 49,792 shares and $1,045,840 in gross proceeds.

How material is the proposed 35,000-share sale to CNTA's outstanding shares?

With 134,073,436 shares outstanding listed, the 35,000-share sale represents about 0.026% of outstanding common stock, indicating limited market impact.

Does the Form 144 state whether the seller has a 10b5-1 trading plan?

No. The filing includes a field for plan adoption or instruction date but does not provide a date or indicate reliance on a 10b5-1 plan.